Gene therapy company Genprex (NASDAQ: GNPX) has added two new executives to its management team: Catherine Vaczy as chief strategy officer and Michael Redman as chief operating officer. Both are executive vice presidents.

Vaczy most recently provided strategic advisory services to early stage biotechnology companies. Previously she co-founded and served for a decade on the leadership team at NeoStem, now Caladrius Biosciences (NASDAQ: CLBS). Her prior experience includes time at ImClone Systems, which was acquired by Eli Lily (NYSE: LLY).

Redman was most recently president and CEO of Oncolix. Previously he was CEO of Bone Medical and… Read more »